Biogen Inc. SEC filings BIIB

Biogen Inc. has 1,001 filings in SEC EDGAR's recent list, going back to Oct 2, 2014. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Oct 28, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 28, 2026 (results of operations). The company's fiscal year ends on December 31.

Biogen Inc. SEC filings
Form Description Filed Period
ARS Annual report to shareholders Apr 28, 2026 Dec 31, 2025
10-K Annual report Feb 6, 2026 Dec 31, 2025
ARS Annual report to shareholders Apr 28, 2025 Dec 31, 2024
10-K Annual report Feb 12, 2025 Dec 31, 2024
ARS Annual report to shareholders Apr 26, 2024 Dec 31, 2023
10-K Annual report Feb 14, 2024 Dec 31, 2023
ARS Annual report to shareholders Apr 28, 2023 Apr 27, 2023
10-K Annual report Feb 15, 2023 Dec 31, 2022
10-K Annual report Feb 3, 2022 Dec 31, 2021
10-K Annual report Feb 3, 2021 Dec 31, 2020
10-K Annual report Feb 6, 2020 Dec 31, 2019
10-K Annual report Feb 6, 2019 Dec 31, 2018
10-K Annual report Feb 1, 2018 Dec 31, 2017
10-K Annual report Feb 2, 2017 Dec 31, 2016
10-K Annual report Feb 3, 2016 Dec 31, 2015
ARS Annual report to shareholders May 1, 2015 Dec 31, 2014
10-K Annual report Feb 4, 2015 Dec 31, 2014

Showing 17 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
BIIB (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Cambridge, MA
SEC filer status
Large accelerated filer
SEC CIK
875045
Former names
BIOGEN IDEC INC. (until Mar 20, 2015); BIOGEN IDEC INC (until Apr 25, 2007); IDEC PHARMACEUTICALS CORP / DE (until Nov 12, 2003); IDEC PHARMACEUTICALS CORP / CA (until Feb 14, 1997)

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.